734 patents currently held
53 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
149
Ending by 2030
Nov 2026
Next term end
383
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2028 · Low confidence
Also notable
Ends Nov 2034 · Medium confidence
Also notable
Ends Nov 2036 · High confidence
Nucleoside Phosphoramidate Prodrugs
US 8,334,270
The most cited patent in this portfolio, cited by 195 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
Pyrrolo[1,2-f][1,2,4]triazines Useful for Treating Respiratory Syncitial Virus Infections
US 10,377,761
Cited by 40 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Vaccines Against Hepatitis B Virus
US 11,214,598
Cited by 12 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2036.
Formerly held, still cited
Notable
Ends Nov 2034 · High confidence
Cited by 90 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
now held by Rosemount Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 30, 2026
- 18 fees due Dec 2 to 30, 2026 · next Dec 2
- 14 fees due Jan 2 to 28, 2027 · next Jan 2
- 14 fees due Feb 4 to 28, 2027 · next Feb 4
- 14 fees due Mar 1 to 26, 2027 · next Mar 1
- 12 fees due Apr 3 to 29, 2027 · next Apr 3
- 9 fees due May 7 to 28, 2027 · next May 7
- 18 fees due Jun 3 to 30, 2027 · next Jun 3
- 7 fees due Jul 2 to 30, 2027 · next Jul 2
- 13 fees due Aug 4 to 27, 2027 · next Aug 4
- 22 fees due Sep 1 to 30, 2027 · next Sep 1
- 5 fees due Oct 2 to 26, 2027 · next Oct 2
- 8 fees due Nov 5 to 12, 2027 · next Nov 5
Recent changes
- Oct 23Assignment recorded on 1 record: Pugh, Catherine and 16 others to Gilead Sciences, Inc. Recorded Oct 23, 2026, executed Dec 16, 2020. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76641, frame 414.
- Sep 15Assignment recorded on 1 record: Leo Pharma A/S to Gilead Sciences, Inc. Recorded Sep 15, 2026, executed Jan 10, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76027, frame 103.
- 5 of the patents on this record were granted since Aug 16, 2026
- 3 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 383 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Nucleoside Phosphoramidate Prodrugs | 10 in force | to Mar 2029 |
| Blister Pack Packaging Blank | 8 in force | to Mar 2040 |
| Nucleoside Phosphoramidates | 8 in force | to Apr 2031 |
| Antiviral Compounds | 8 in force | to May 2030 |
| Modulators of Toll-Like Receptors | 7 in force | to Dec 2030 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,642,339 | Antiviral Compounds In force · High confidence | In force | High confidence | |
| US 9,579,332 | Phosphonate Analogs of HIV Inhibitor Compounds In force · High confidence | In force | High confidence | |
| US 7,600,568 | Safety Vent Valve In force · High confidence | In force | High confidence | |
| US 7,871,991 | Phosphonate Analogs of HIV Inhibitor Compounds In force · High confidence | In force | High confidence | |
| US 7,956,179 | Process for Preparing an A2A-ADENOSINE Receptor Agonist and Its Polymorphs In force · High confidence | In force | High confidence | |
| US 8,106,183 | Process for Preparing an A2A-ADENOSINE Receptor Agonist and Its Polymorphs In force · Medium confidence | In force | Medium confidence | |
| US 8,268,988 | Process for Preparing an A2A-ADENOSINE Receptor Agonist and Its Polymorphs In force · Medium confidence | In force | Medium confidence | |
| US 8,524,883 | Monohydrate of (1-{9-[(4S,2R,3R,5R)-3,4-Dihydroxy-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6-Aminopurin-2-YL}PYRAZOL-4-YL)-N-METHYLCARBOXAMIDE In force · Medium confidence | In force | Medium confidence | |
| US RE47,301 | Process for Preparing an A2A-ADENOSINE Receptor Agonist and Its Polymorphs In force · Low confidence | In force | Low confidence | |
| US 8,431,745 | Process for Preparation of HIV Protease Inhbitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 734: 53 patents in force now held by others · 234 patents ended · 210 applications pending · 511 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.